A
Ashish M. Kamat
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 20033
Ashish M. Kamat is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Bladder cancer & Cystectomy. The author has an hindex of 67, co-authored 507 publications receiving 15989 citations. Previous affiliations of Ashish M. Kamat include University of Texas Health Science Center at San Antonio & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration
Vitaly Margulis,Shahrokh F. Shariat,Surena F. Matin,Ashish M. Kamat,Richard Zigeuner,Eiji Kikuchi,Yair Lotan,Alon Z. Weizer,Jay D. Raman,Christopher G. Wood +9 more
TL;DR: In this article, a large series of patients treated with radical nephroureterectomy for urothelial carcinoma were studied, and variables associated with poor prognosis were identified.
Journal ArticleDOI
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
Sam S. Chang,Bernard H. Bochner,Roger Chou,Robert Dreicer,Ashish M. Kamat,Seth P. Lerner,Yair Lotan,Joshua J. Meeks,Jeff M. Michalski,Todd M. Morgan,Diane Zipursky Quale,Jonathan E. Rosenberg,Anthony L. Zietman,Jeffrey M. Holzbeierlein +13 more
TL;DR: This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.
Journal ArticleDOI
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
Chrysoula I. Liakou,Ashish M. Kamat,Derek Ng Tang,Hong Chen,Jingjing Sun,Patricia Troncoso,Christopher J. Logothetis,Padmanee Sharma +7 more
TL;DR: It is found that CD4 T cells from peripheral blood and tumor tissues of all treated patients had markedly increased expression of inducible costimulator (ICOS), which are the first immunologic changes reported in both tumor tissues and peripheral blood as a result of treatment with anti-CTLA-4 antibody.
Journal ArticleDOI
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
Marcus G. Cumberbatch,Ibrahim Jubber,Peter C. Black,Francesco Esperto,Jonine D. Figueroa,Ashish M. Kamat,Lambertus A. Kiemeney,Yair Lotan,Karl H. Pang,Debra T. Silverman,Ariana Znaor,James W.F. Catto +11 more
TL;DR: Evidence is emerging regarding gene-environment interactions, particularly for tobacco and occupational exposures, and standardisation of reporting may help improve epidemiologic evaluation of risk.
Journal ArticleDOI
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Bradley C. Carthon,Jedd D. Wolchok,Jianda Yuan,Ashish M. Kamat,Derek Ng Tang,Jingjing Sun,Geoffrey Y. Ku,Patricia Troncoso,Christopher J. Logothetis,James P. Allison,Padmanee Sharma +10 more
TL;DR: The trial shows that anti–CTLA-4 therapy has a tolerable safety profile in the presurgical setting and that a preoperative model can be used to obtain biological data on human immune responses, which can efficiently guide the monitoring of patients treated in the metastatic disease setting.